Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients

30 Jun 2023

Abstract excerpt

In the Amazon, the treatment for Plasmodium vivax is chloroquine plus primaquine. However, this regimen is limited due to the risk of acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Primaquine is a prodrug that requires conversion by the CYP2D6 enzyme to be effective against malaria. A series of cases were performed at an infectious diseases reference hospital in the Western Brazilian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Metabolism and Genetic Disorders
Share to Methemoglobinemia and Tumor Lysis Syndrome
Share to Neonatal Health and Biochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37513742
DOI: 10.3390/pathogens12070895

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient PatientsPMID 37513742Read ↗

Influence of CYP2C19, CYP2D6 and CYP3A4 genetic variants on the biological effect of malaria treatment with primaquine in G6PD- deficient and G6PD-normal patientsSemantic proximity Read ↗

G6PD deficiency: global distribution, genetic variants and primaquine therapy.Semantic proximity Read ↗

G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.Semantic proximity Read ↗

Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.Semantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.Semantic proximity Read ↗

Glucose-6-phosphate dehydrogenase deficiencySemantic proximity Read ↗

High prevalence of G6PD mutations in blood donors from the Brazilian Amazon region.Semantic proximity Read ↗

Glucose-6-phosphate dehydrogenase deficient variants are associated with reduced susceptibility to malaria in the Brazilian Amazon.Semantic proximity Read ↗

Prevalence and genetic variants of G6PD deficiency among malaria suspected patients in Shele and Lante Health Center, Southern EthiopiaSemantic proximity Read ↗

Prevalence of G6PD Deficiency and Distribution of Its Genetic Variants Among Malaria-Suspected Patients Visiting Metehara Health Center, Eastern EthiopiaSemantic proximity Read ↗

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.